Acute Myeloid Leukemia (AML)
Health-Related Quality of Life, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium
MDS and Secondary AML Pathophysiology, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium
Non-Transplant Therapies for Marrow Failure, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium
Pathways of Clonal Progression Arising from Germline Predisposition, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium
Urge Your U.S. Senators to Support the Bipartisan Letter to Increase Medical Research Accounts in the DoD
Donor T cells on double duty: VCAR33 for AML after transplant
In this issue of Blood, Mushtaq et al1 report on a phase 1/2 trial (NCT05984199, known as Vor Biopharma trial VBP301) utilizing donor-derived anti-CD33 chimeric antigen receptor–modified (CAR) T cells (VCAR33) in patients with relapsed acute myeloid leukemia (AML) following…
How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide
Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy
Abstract The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to…
Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax
Abstract Venetoclax (Ven) in combination with hypomethylating agents (HMA) (azacitidine or decitabine) is the standard of care for elderly or unfit patients with acute myeloid leukemia (AML) and is being explored in high-risk myelodysplastic syndrome (HR-MDS). However, currently…
